Clinical Trial Update: Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update for the SToMP-AD Alzheimer's disease study indicates the senolytic therapy is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• Senolytic therapy (SToMP-AD)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Alzheimer Disease, Early Onset, Mild Cognitive Impairment | Phase 2 | Status: ACTIVE_NOT_RECRUITING